BioScrip (BIOS) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Jefferies Resumes BioScrip (BIOS) at Buy
November 8, 2016 7:22 AM ESTJefferies resumes coverage on BioScrip (NASDAQ: BIOS) with a Buy rating and a price target of $2.50.
Analyst Brian Tanquilut commented, "We were surprised by BIOS's disappointing Q3 and the resulting guidance cut, and recognize that it further dents the company's already-weak credibility... More
